ويكيبيديا

قائمة الأجسام المضادة وحيدة النسيلة: الفرق بين النسختين

تصفح التاريخ تفاعلياً
[نسخة منشورة][نسخة منشورة]
→ التعديل السابقالتعديل اللاحق ←
تم حذف المحتوى تمت إضافة المحتوى
مرئينص الويكي
ElphiBot (نقاش | مساهمات)
606٬816 edits
ZkBot (نقاش | مساهمات)
2٬140٬655 edits
سطر 7:
== مصطلحات ومختصرات ==
مختصرات عمود ''النوع'' موضحة كما يلي:
 
* جسم مضاد وحيد النسيلة كاملاً: '''mab'''
* الشدفة الرابطة للجسم المضاد: '''Fab''' (ذراع واحد)
السطر 28 ⟵ 27:
| [[3F8]] || || mab || فأر || [[w:GD2]] || [[ورم الخلايا البدائية العصبية]]
|-
| [[8H9]]<ref name=Ch1418 /> || || mab || فأر || [[w:B7-H3|B7-H3]] || [[ورم الخلايا البدائية العصبية]] وال[[غرن]] و[[سرطان الدماغ|سرطانات الدماغ النقيلية]]
|-
| [[أباغوفوماب]]<ref name=WHOList95 /> || || mab || فأر || [[w:CA-125]] (imitation) || [[سرطان المبيض]]
|-
| [[أبسيكسيماب]] || ريو برو (ReoPro)|| Fab || مجانس || [[w:CD41]] (integrin alpha-IIb) || [[مضاد تجمع الصفيحات]]
|-
| [[آكتوكسوماب]]<ref name=Actoxumab /> || || mab || بشري || ''[[كلوستريديوم ديفيسيلي]]'' || عدوى ''[[كلوستريديوم ديفيسيلي]]''
|-
| [[أداليموماب]] || هوميرا (Humira)|| mab || بشري || [[w:TNF-α]] || [[التهاب المفاصل الروماتويدي]] و[[داء كرون]] و[[صداف]] اللوحي و[[التهاب المفاصل الصدافي]] و[[التهاب الفقار المقسط]] و[[التهاب المفاصل الرثياني الشبابي]]
|-
| [[أديكاتوموماب]]<ref name=WHOList90 /> || || mab || بشري || [[w:EpCAM]] || [[سرطان الموثة]] و[[سرطان الثدي]]
|-
| [[أفيليموماب]] || || F(ab')<sub>2</sub> || فأر || [[w:TNF-α]] || [[إنتان]]
|-
| [[أفوتوزوماب]]<ref name=WHOList99 /> || || mab || مأنسن || [[w:CD20]] || [[ورم لمفي]]
|-
| [[ألاسيزوماب بيغول]]<ref name=WHOList98 /> || || F(ab')<sub>2</sub> || مانسن || [[w:VEGFR2]] || [[سرطان]]
|-
| [[ALD518]]<ref name="ALD518" /> || || ؟ || مأنسن || [[إنترليوكين 6|IL-6]] || [[التهاب المفاصل الروماتويدي]]
|-
| [[أليمتوزوماب]]<ref name=WHOList83 /> || كامباث (Campath)<br />مابكامباث (MabCampath)|| mab || مأنسن || [[w:CD52]] || [[ابيضاض الدم الليمفاوي المزمن]] و[[الورم اللِمفي الجلديّ للكريات الليمفاوية التائية]]
|-
| [[أليروكوماب]]<ref name=Alirocumab /> || || mab || بشري || NARP-1 || [[ارتفاع الكولسترول]]
|-
| [[ألتوموماب بنتيتات]] || هايبري-كيكر (Hybri-ceaker) || mab || فأر || {{وإو|جسم مضاد سرطاني جنيني|Carcinoembryonic antigen}} || للكشف عن [[سرطان القولون]]
|-
| [[أماتوكسيماب]]<ref name=Amatuximab /> || || mab || مجانس || [[w:MORAb-009]] || سرطان
|-
| [[أناتوموماب مافيناتوكس]] || || Fab || فأر || {{وإو|بروتين سكري مرتبط بالورم 72|Tumor-associated glycoprotein 72}} || [[سرطان خلايا الرئة غير الصغيرة]]
|-
| [[أنروكينزوماب]]<ref name=WHOList98 /> (= IMA-638)<ref name="IMA-638" /> || || mab || مأنسن || [[Interleukin 13|IL-13]] || ؟
|-
| [[أبوليزوماب]]<ref name=WHOList87 /> || || mab || مأنسن || [[HLA-DR]] ؟ || [[ورم الدم|أورام الدم]]
|-
| [[أرسيتوموماب]] || CEA-Scan || Fab' || فأر || {{وإو|جسم مضاد سرطاني جنيني|Carcinoembryonic antigen}} || سرطانات القناة الهضمية (تجريبي)
|-
| [[أسيليزوماب]]<ref name=WHOList88 /> || || mab || مأنسن || [[L-selectin]] (CD62L) || المرضى المصابون إصابات شديدة
|-
| [[أتينوماب]]<ref name=WHOList104 /> || || mab || بشري || [[RTN4]] || ؟
|-
| [[أتليزوماب]] (= توسيليزوماب) || Actemra, RoActemra || mab || مأنسن || [[IL-6 receptor]] || [[التهاب المفاصل الروماتويدي]]
السطر 72 ⟵ 71:
| [[أتوروليموماب]] || || mab || بشري || [[Rhesus factor]] || [[مرض تحلل الدم في حديثي الولادة]]{{حقيقة|date=November 2012}}
|-
| [[بابينيوزوماب]]<ref name=WHOList93 /> || || mab || مأنسن || [[beta amyloid]] || [[مرض ألزهايمر]]
|-
| [[باسيليكسيماب]] || Simulect || mab || مجانس || [[CD25]] (α chain of [[interleukin 2|IL-2]] receptor) || منع [[رفض الطعم]]
|-
| [[بافيتوكسيماب]]<ref name=WHOList95 /> || || mab || مجانس || [[phosphatidylserine]] || السرطان والعدوى الفايروسية
|-
| [[بكتوموماب]] || LymphoScan || Fab' || فأر || [[CD22]] || [[لمفومة لاهودجكينية]] (الكشف)
السطر 84 ⟵ 83:
| [[بنراليزوماب]] || || mab || مأنسن || [[CD125]] || ال[[ربو]]
|-
| [[برتيليموماب]]<ref name=WHOList88 /> || || mab || بشري || [[CCL11]] (eotaxin-1) || أعراض الحساسية الحادة
|-
| [[بسيليموماب]]<ref name=WHOList92 /> || Scintimun || mab || فأر || جسم مضاد متعلق بـ{{وإو|جسم مضاد سرطاني جنيني|Carcinoembryonic antigen}} || الندب الإلتهابية [[نقيلة|والنقيلات]] (للكشف)
|-
| [[بيفاسيزوماب]]<ref name=WHOList83 /> || Avastin || mab || مأنسن || [[Vascular endothelial growth factor A|VEGF-A]] || [[نقيلة|سرطان نقيلي]]
|-
| [[بزلوتوكسوماب]]<ref name=Bezlotoxumab /> || || mab || بشري || ''[[كلوستريديوم ديفيسيلي]]'' || عدوى ''[[كلوستريديوم ديفيسيلي]]''
|-
| [[بيسيروماب]] || FibriScint || Fab' || فأر || [[fibrin]] II, beta chain || [[جلطة دموية]] (تشخيص)
السطر 98 ⟵ 97:
| [[بليناتوموماب]] || || BiTE || فأر || [[CD19]] || سرطان
|-
| [[بلوسوزوماب]]<ref name=WHOList105 /> || || mab || مأنسن || [[SOST]] || [[تخلخل العظم]]
|-
| [[برنتوكسيماب فيدوتين]]<ref name="Brentuximab vedotin" /> || || mab || مجانس || [[CD30]] (TNFRSF8) || [[ورم الدم|أورام الدم]]
|-
| [[برياكينوماب]]<ref name=Briakinumab /> || || mab || بشري || [[interleukin-12|IL-12]], [[interleukin-23|IL-23]] || ال[[صداف]] و[[التهاب المفاصل الروماتويدي]] و[[داء الأمعاء الالتهابي]] و[[التصلب اللويحي]]
|-
| [[برودالوماب]]<ref name=Brodalumab /> || || mab || بشري || [[interleukin-17|IL-17]] || أمراض إلتهابية
|-
| [[كاناكينوماب]]<ref name=WHOList97 /> || Ilaris || mab || بشري || [[Interleukin 1|IL-1]]؟ || [[التهاب المفاصل الروماتويدي]]
|-
| [[كانتوزوماب مرتانسين]] || || mab || مأنسن || [[mucin]] CanAg || [[سرطان القولون]]... الخ.
|-
| [[كانتوزوماب رافتانسين]]<ref name=WHOList105 /> || || mab || مأنسن || MUC1 || سرطانات
|-
| [[كابلاسيزوماب]]<ref name=WHOList106 /> || || mab || مأنسن || VWF || ؟
|-
| [[كابروماب بنديتايد]] || Prostascint || mab || فأر || prostatic carcinoma cells || للكشف عن [[سرطان الموثة]]
|-
| [[كارلوماب]]<ref name=Carlumab /> || || mab || بشري || [[CNTO888]] || استخدامات علاجية لحالات [[علم الأورام|الأورام]] وال[[جهاز مناعي|مناعة]]
|-
| [[كاتوماكسوماب]]<ref name=WHOList93 /> || Removab || 3funct || مهجن جرذ/فأر || [[EpCAM]], [[CD3 (immunology)|CD3]] || [[سرطان المبيض]] وال[[حبن]] الخبيث و[[سرطان المعدة]]
|-
| [[CC49]] || || mab || فأر || [[Tumor-associated glycoprotein 72|TAG-72]] || الكشف عن الأورام
السطر 124 ⟵ 123:
| [[سيديليزوماب]] || || mab || مأنسن || [[كتلة التمايز 4]] || منع [[رفض الطعم]] وعلاج [[أمراض المناعة الذاتية]]
|-
| [[سرتوليزوماب بيغول]]<ref name=WHOList90 /> || Cimzia || Fab' || مأنسن || [[TNF-α]] || [[داء كرون]]
|-
| [[سيتوكسيماب]] || Erbitux || mab || مجانس || [[Epidermal growth factor receptor|EGFR]] || [[سرطان القولون]] النقيلي و[[سرطان الرأس والعنق]]
السطر 130 ⟵ 129:
| [[Ch.14.18]] <ref name=Ch1418/> || || mab || مجانس || ؟؟؟ || [[ورم الخلايا البدائية العصبية]]
|-
| [[سيتاتوزوماب بوغاتوكس]]<ref name=WHOList99 /> || || Fab || مأنسن || [[EpCAM]] || [[سرطان المبيض]] والأورام الصلبة الأخرى
|-
| [[سيكسوتوموماب]] || || mab || بشري || [[IGF-1 receptor]] || أورام صلبة
|-
| [[كلازاكيزوماب]]<ref name=Clazakizumab /> || || mab || مأنسن || ''Oryctolagus cuniculus'' || [[التهاب المفاصل الروماتويدي]]
|-
| [[كلينوليكسيماب]] || || mab || مجانس || [[كتلة التمايز 4]] || [[التهاب المفاصل الروماتويدي]]
|-
| [[كليفاتوزوماب تتراكسيتان]]<ref name="Clivatuzumab tetraxetan" /> || hPAM4-Cide || mab || مأنسن || [[MUC1]] || [[ورم البنكرياس]]
|-
| [[كوناتوموماب]]<ref name=WHOList99 /> || || mab || بشري || [[TRAIL-R2]] || سرطان
|-
| [[كرينيزوماب]]<ref name="Crenezumab"/> || || mab || مأنسن || [[MABT5102A]] || [[مرض ألزهايمر]]
السطر 146 ⟵ 145:
| [[CR6261]] || || mab || بشري || [[Hemagglutinin (influenza)|Influenza A hemagglutinin]] || أمراض معدية/[[فيروس إنفلونزا أ]]
|-
| [[داستوزوماب]]<ref name=WHOList98 /> || || mab || مأنسن || [[CD40]] || سرطانات الدم
|-
| [[داكليزوماب]] || Zenapax || mab || مأنسن || [[CD25]] (α chain of [[interleukin 2|IL-2]] receptor) || منع [[رفض الطعم]]
|-
| [[دالوتوزوماب]]<ref name=Dalotuzumab /> || || mab || مأنسن || insulin-like growth factor I receptor || سرطان... الخ
|-
| [[داراتوموماب]]<ref name=WHOList101 /> || || mab || بشري || [[CD38]] (cyclic ADP ribose hydrolase) || ؟
|-
| [[دمسيزوماب]]<ref name=Demcizumab /> || || mab || مأنسن || DLL4 || سرطان
|-
| [[دينوسوماب]]<ref name=WHOList94 /> || Prolia || mab || بشري || [[RANKL]] || [[تخلخل العظم]] وانبثاث العظام... الخ
|-
| [[ديتوموماب]] || || mab || فأر || B-lymphoma cell || ورم لمفي
|-
| [[دورليموماب آريتوكس]]<ref name=WHOList66 /> || || F(ab')<sub>2</sub> || فأر || ؟ || ؟
|-
| [[دروزيتوماب]]<ref name=Drozitumab /> || || mab || بشري || [[TNFRSF10B|DR5]] || سرطان... الخ
|-
| [[دوليغوتوماب]]<ref name=WHOList107 /> || || mab || بشري || [[HER3]] || ؟
|-
| [[دوبيلوماب]]<ref name=Dupilumab /> || || mab || بشري || [[Interleukin 4|IL4]] || أمراض استشرائية
|-
| [[دوسيجيتوماب]]<ref name=Dusigitumab /> || || mab || بشري || [[Insulin-like growth factor II|ILGF2]] || سرطان
|-
| [[إكرومكسيماب]]<ref name=WHOList87 /> || || mab || مجانس || GD3 [[ganglioside]] || [[ورم ميلانيني]] خبيث
|-
| [[إيكوليزوماب]]<ref name=WHOList87 /> || Soliris || mab || مأنسن || [[Complement component 5|C5]] || [[بيلة هيمغلوبينية انتيابية ليلية|البيلة الهيمُغلوبينية الانتيابية الليلية]]
|-
| [[إدوباكوماب]] || || mab || فأر || [[endotoxin]] || [[إنتان]] سببه [[بكتيريا سلبية الغرام]]
السطر 178 ⟵ 177:
| [[إدريكولوماب]] || Panorex || mab || فأر || [[EpCAM]] || [[سرطان القولون]]
|-
| [[إيفاليزوماب]]<ref name=WHOList85 /> || Raptiva || mab || مأنسن || [[LFA-1]] ([[CD11a]]) || ال[[صداف]] (يسد هجرة [[خلية تائية|الخلايا التائية]])
|-
| [[إفونغوماب]]<ref name=WHOList95 /> || Mycograb || scFv || بشري || [[Hsp90]] || [[داء المبيضات]] الشديد
|-
| [[إلوتوزوماب]] || || mab || مأنسن || [[SLAMF7]] || [[ورم نقوي متعدد]]
السطر 186 ⟵ 185:
| [[إلسيليموماب]] || || mab || فأر || [[Interleukin 6|IL-6]] || ؟
|-
| [[إينافاتوزوماب]]<ref name=Enavatuzumab /> || || mab || مأنسن || [[PDL192]] || سرطان... الخ
|-
| [[إنليموماب بيغول]]<ref name=WHOList77 /> || || mab || فأر || [[ICAM-1]] (CD54) || ؟
|-
| [[إينوكيزوماب]]<ref name=Enokizumab /> || || mab || مأنسن || [[MEDI-528]] || ال[[ربو]]
|-
| [[إينوتيكوماب]]<ref name=WHOList107 /> || || mab || بشري || [[DLL4]] || ؟
|-
| [[إنسيتوكسيماب]]<ref name=Ensituximab /> || || mab || مجانس || [[NPC-1C]] || سرطان
|-
| [[إبيتوموماب سيتوكسيتان]]<ref name=WHOList51 /> || || mab || فأر || episialin || ؟
|-
| [[إبراتوزوماب]] || || mab || مأنسن || [[CD22]] || سرطان, [[الذئبة الحمامية الجهازية]]
|-
| [[إرليزوماب]]<ref name=WHOList84 /> || || F(ab')<sub>2</sub> || مأنسن || [[ITGB2]] (CD18) || [[احتشاء عضل القلب]] و[[سكتة دماغية|السكتة الدماغية]] و[[صدمة (طب)|الصدمة]]
|-
| [[إرتوماكسوماب]]<ref name=WHOList93/> || Rexomun || 3funct || مهجن جرذ/فأر || [[HER2/neu]], [[CD3 (immunology)|CD3]] || [[سرطان الثدي]]... الخ
السطر 206 ⟵ 205:
| [[إيتاراسيزوماب]] || Abegrin || mab || مأنسن || [[integrin]] [[alpha-v beta-3|α<sub>v</sub>β<sub>3</sub>]] || [[ورم ميلانيني]] و[[سرطان الموثة]] و[[سرطان المبيض]] ...الخ.
|-
| [[إتروليزوماب]]<ref name=Etrolizumab /> || || mab || مأنسن || [[rhuMAb β7]] || [[داء الأمعاء الالتهابي]]
|-
| [[إيفولوكوماب]]<ref name=WHOList108 /> || || mab || بشري || [[PCSK9]] || [[انخفاض الكوليسترول]]
|-
| [[إكسبيفيروماب]]<ref name=WHOList91 /> || || mab || بشري || سطح أنتيجين [[فيروس التهاب الكبد الفيروسي ب]] || التهاب الكبد الوبائي ب
|-
| [[فانوليسوماب]]<ref name=WHOList86/> || NeutroSpec || mab || فأر || [[CD15]] || [[التهاب الزائدة الدودية]] (diagnosis)
السطر 218 ⟵ 217:
| [[فارليتوزوماب]] || || mab || مأنسن || [[folate receptor 1]] || [[سرطان المبيض]]
|-
| [[فاسينوماب]]<ref name=Fasinumab /> || || mab || بشري || [[عامل نمو الأعصاب|HNGF]] || ؟
|-
| [[FBTA05]]<ref>{{cite journal | last1=Buhmann| first1=R | last2=et al | title=Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion| journal=Bone Marrow Transplantation | volume=43 | issue=5| pages=383–397 | year=2008 | pmid=18850012 | first2=B | last3=Stanglmaier | first3=M | last4=Yang | first4=T | last5=Faltin | first5=M | last6=Bund | first6=D | last7=Lindhofer | first7=H | last8=Kolb | first8=HJ | doi=10.1038/bmt.2008.323}}</ref><ref>{{cite journal | last1=Boehrer| first1=S | last2=et al | title= Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms | journal=Anti-Cancer Drugs |volume=12 | issue=10| pages=3085–3091 | year=2011 | url=http://journals.lww.com/anti-cancerdrugs/Abstract/publishahead/Cytotoxic_effects_of_the_trifunctional_bispecific.99702.aspx | doi=10.1097/CAD.0b013e328344887f | first2=Petra | last3=Mueller | first3=Tina | last4=Atz | first4=Judith | last5=Chow | first5=Kai Uwe}}</ref> || Lymphomun || 3funct || مهجن جرذ/فأر || [[CD20]] || [[ابيضاض الدم الليمفاوي المزمن]]
السطر 224 ⟵ 223:
| [[فلفيزوماب]] || || mab || مأنسن || [[فيروس مخلوي تنفسي|الفيروس المخلوي التنفسي]] || عدوى [[فيروس مخلوي تنفسي|فيروس الجهاز التنفسي المخلوي]]
|-
| [[فيزاكينوماب]]<ref name=Fezakinumab /><ref name=NCT00883896 /><ref name=NCT00563524 /> || || mab || بشري || [[Interleukin 22|IL-22]] || [[التهاب المفاصل الروماتويدي]] وال[[صداف]]
|-
| [[فيكلاتوزوماب]]<ref name=Ficlatuzumab /> || || mab || مأنسن || [[SCH 900105]] || سرطان... الخ
|-
| [[فيجيتوموماب]] || || mab || بشري || [[IGF-1 receptor]] || [[adrenocortical carcinoma]], [[non-small cell lung carcinoma]] etc.
|-
| [[فلانفوتوماب]]<ref name=Flanvotumab /> || || mab || بشري || [[glycoprotein 75]] || [[ورم ميلانيني]]
|-
| [[فونتوليزوماب]]<ref name=WHOList87 /> || HuZAF || mab || مأنسن || [[IFN-γ]] || [[داء كرون]]... الخ
|-
| [[فورالوماب]]<ref name=WHOList103 /> || || mab || بشري || [[CD3 epsilon]] || ؟
|-
| [[فورافيروماب]]<ref name=WHOList99 /> || || mab || بشري || [[rabies]] virus glycoprotein || [[داء الكلب]] (وقاية)
|-
| [[فريسوليموماب]]<ref name=Fresolimumab /> || || mab || بشري || [[TGF-β]] || [[تليف رئوي مجهول السبب]], [[focal segmental glomerulosclerosis]], سرطان
|-
| [[فولرانوماب]]<ref name=Fulranumab /> || || mab || بشري || [[عامل نمو الأعصاب|NGF]] || [[ألم]]
|-
| [[فوتوكسيماب]]<ref name=WHOList107 /> || || mab || مجانس || [[Epidermal growth factor receptor|EGFR]] || ؟
|-
| [[غاليكسيماب]] || || mab || مجانس || [[CD80]] || [[ورم لمفي|ورم لمفي للخلايا البائية]]
|-
| [[غانيتوماب]]<ref name=Ganitumab /> || || mab || بشري || [[IGF-I]] || سرطان
|-
| [[غانتينيروماب]]<ref name=WHOList97 /> || || mab || بشري || [[beta amyloid]] || [[مرض ألزهايمر]]
|-
| [[غافيليموماب]]<ref name=WHOList84 /> || || mab || فأر || [[باسيجين]] (basigin) || [[داء الطعم حيال الثوي]]
|-
| [[جيمتوزوماب أوزوغاميسين]] || Mylotarg || mab || مأنسن || [[CD33]] || [[ابيضاض الدم النقوي الحاد]]
|-
| [[جيفوكيزوماب]]<ref name=Gevokizumab /> || || mab || مأنسن || [[IL-1β]] || [[السكري]] etc.
|-
| [[جيرنتوكسيماب]]<ref name=WHOList101 /> || Rencarex || mab || مجانس || [[carbonic anhydrase 9]] (CA-IX)|| clear cell [[renal cell carcinoma]]<ref>http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html</ref>
|-
| [[غلمباتوموماب فيدوتين]]<ref name=WHOList102 /><ref name="Glembatumumab" /> || || mab || بشري || [[GPNMB]] || [[ورم ميلانيني]] و[[سرطان الثدي]]
|-
| [[غوليموماب]]<ref name=WHOList91 /> || Simponi || mab || بشري || [[TNF-α]] || [[التهاب المفاصل الروماتويدي]], [[التهاب المفاصل الصدافي]] و[[التهاب الفقار المقسط]]
|-
| [[غوميليكسيماب]] || || mab || مجانس || [[CD23]] ([[IgE receptor]]) || [[ربو|الربو التحسسي]]
السطر 266 ⟵ 265:
| [[GS6624]] <ref name=GS6624/> || || mab || ؟ || ؟ || [[تليف رئوي]] غير معروف السبب والأورام الصلبة
|-
| [[إيباليزوماب]]<ref name=WHOList97 /> || || mab || مأنسن || [[كتلة التمايز 4]] || [[متلازمة العوز المناعي المكتسب]]
|-
| [[إبريتوموماب تيوكسيتان]] || Zevalin || mab || فأر || [[CD20]] || [[لمفومة لاهودجكينية]]
|-
| [[إكروكوماب]]<ref name=Icrucumab /> || || mab || بشري || [[VEGFR-1]] || سرطان... الخ
|-
| [[إيغوفوماب]] || Indimacis-125 || F(ab')<sub>2</sub> || فأر || [[CA-125]] || لتشخيص [[سرطان المبيض]]
|-
| [[إمسيروماب]] || Myoscint || mab || فأر || ال[[ميوزين]] ال[[قلب|قلبي]]ي || تصوير ال[[قلب]]
|-
| [[إمغاتوزوماب]]<ref name=WHOList107 /> || || mab || مأنسن || [[Epidermal growth factor receptor|EGFR]] || سرطان
|-
| [[إنكلاكوماب]]<ref name=WHOList106 /> || || mab || بشري || selectin P || ؟
|-
| [[إنداتوكسيماب رافتانسين]]<ref name=WHOList105 /> || || mab || مجانس || [[SDC1]] || سرطان
|-
| [[إنفلاكسيماب]] || Remicade || mab || مجانس || [[TNF-α]] || [[التهاب المفاصل الروماتويدي]] و[[التهاب الفقار المقسط]] و[[التهاب المفاصل الصدافي]] وال[[صداف]] و[[داء كرون]] و[[التهاب القولون التقرحي]]
|-
| [[إنتيتوموماب]]<ref name=Intetumumab /><ref name=NCT00537381 /><ref name=NCT00246012 /> || || mab || بشري || [[CD51]] || الأورام الصلبة ([[سرطان الموثة]] و[[ورم ميلانيني]])
|-
| [[إينوليموماب]] || || mab || فأر || [[CD25]] (α chain of [[Interleukin 2|IL-2]] receptor) || [[داء الطعم حيال الثوي]]
|-
| [[إينوتوزوماب أوزوغاميسين]]<ref name=WHOList92 /> || || mab || مأنسن || [[CD22]] || سرطان
|-
| [[إيبيليموماب]]<ref name=WHOList94 /> || Yervoy || mab || بشري || [[CD152]] || [[ورم ميلانيني]]
|-
| [[إيراتوموماب]]<ref name=WHOList94 /> || || mab || بشري || [[CD30]] (TNFRSF8) || [[لمفومة لاهودجكينية]]
|-
| [[إيتوليزوماب]]<ref name=WHOList103 /> || || mab || مأنسن || [[CD6]] || ؟
|-
| [[إيكسيكيزوماب]]<ref name=Ixekizumab /> || || mab || مأنسن || [[IL-17A]] || [[أمراض المناعة الذاتية]]
|-
| [[كيليكسيماب]] || || mab || مجانس || [[كتلة التمايز 4]] || ال[[ربو]] المزمن
|-
| [[ليبيتوزوماب]]<ref name=WHOList85 /> || CEA-Cide || mab || مأنسن || {{وإو|جسم مضاد سرطاني جنيني|Carcinoembryonic antigen}} || [[سرطان القولون]]
|-
| [[لامباليزوماب]]<ref name=WHOList107 /> || || mab || مأنسن || [[Complement factor D|CFD]] || ؟
|-
| [[لبريكيزوماب]]<ref name=Lebrikizumab /> || || mab || مأنسن || [[Interleukin 13|IL-13]] || ال[[ربو]]
|-
| [[ليماليسوماب]]<ref name=WHOList84 /> || || mab || فأر || NCA-90 (granulocyte antigen) || أداة تشخيصية
|-
| [[لردليموماب]]<ref name=WHOList83 /> || || mab || بشري || [[TGF beta 2]] || التقليل من التندب بعد [[جراحة الزرق]]
|-
| [[لكساتوموماب]]<ref name=WHOList95 /> || || mab || بشري || [[TRAIL-R2]] || سرطان
|-
| [[ليبيفيروماب]]<ref name=WHOList91 /> || || mab || بشري || أنتيجين سطح فيروس [[التهاب الكبد ب]] || [[التهاب الكبد ب]]
|-
| [[ليجيليزوماب]]<ref name=WHOList107 /> || || mab || مأنسن || [[IGHE]] || ؟
|-
| [[لينتوزوماب]] || || mab || مأنسن || [[CD33]] || سرطان
|-
| [[ليريلوماب]]<ref name=WHOList107 /> || || mab || بشري || [[KIR2D]] || ؟
|-
| [[لورفوتوزوماب مرتانسين]] || || mab || مأنسن || [[CD56]] || سرطان
|-
| [[لوكاتوموماب]]<ref name=WHOList98 /> || || mab || بشري || [[CD40]] || [[ورم نقوي متعدد|الورم النقوي المتعدد]] و[[لمفومة لاهودجكينية|اللمفومة اللاهودجكينية]] و[[لمفومة هودجكين]]
|-
| [[لوميليكسيماب]]<ref name=WHOList90 /> || || mab || مجانس || [[CD23]] ([[IgE receptor]]) || [[ابيضاض الدم الليمفاوي المزمن]]
|-
| [[ماباتوموماب]]<ref name=WHOList93 /> || || mab || بشري || [[TRAIL]]-R1 || سرطان
|-
| [[ماسليموماب]] || || ؟ || فأر || T-cell receptor || ؟
|-
| [[مافريليموماب]]<ref name=Mavrilimumab /> || || mab || بشري || [[CAM-3001]] || [[التهاب المفاصل الروماتويدي]]
|-
| [[ماتوزوماب]]<ref name=WHOList88 /> || || mab || مأنسن || [[Epidermal growth factor receptor|EGFR]] || [[سرطان القولون]] وسرطان الرئة والمعدة
|-
| [[ميبوليزوماب]] || Bosatria || mab || مأنسن || [[Interleukin 5|IL-5]] || ال[[ربو]] وأمراض كريات الدم البيض
|-
| [[ميتيليموماب]]<ref name=WHOList86 /> || || mab || بشري || [[TGF beta 1]] || [[systemic scleroderma]]
|-
| [[ميلاتوزوماب]]<ref name=WHOList98 /> || || mab || مأنسن || [[CD74]] || [[ورم نقوي متعدد|الورم النقوي المتعدد]] وأورام الدم الأخرى
|-
| [[مينريتوموماب]] || || mab || فأر || [[Tumor-associated glycoprotein 72|TAG-72]] || ؟
السطر 344 ⟵ 343:
| [[ميتوموماب]] || || mab || فأر || GD3 [[ganglioside]] || [[small cell lung carcinoma]]
|-
| [[موغاموليزوماب]]<ref name=Mogamulizumab /> || || mab || مأنسن || [[CCR4]] || سرطان
|-
| [[موروليموماب]] || || mab || بشري || [[Rhesus factor]] || ؟
|-
| [[موتافيزوماب]]<ref name=WHOList95 /> || Numax || mab || مأنسن || [[فيروس مخلوي تنفسي|الفيروس المخلوي التنفسي]] || [[فيروس مخلوي تنفسي|الفيروس المخلوي التنفسي]] (منع)
|-
| [[موكسيتوموماب باسودوتوكس]]<ref name="Moxetumomab pasudotox" /> || || mab || فأر || [[CD22]] || سرطان
|-
| [[موروموناب - سي دي 3]] || Orthoclone OKT3 || mab || فأر || [[CD3 (immunology)|CD3]] || منع [[رفض الطعم]]
السطر 356 ⟵ 355:
| [[ناكولوماب تافيناتوكس]] || || Fab || فأر || C242 antigen || [[سرطان القولون]]
|-
| [[ناميلوماب]]<ref name=WHOList104 /> || || mab || بشري || [[CSF2]] || ؟
|-
| [[نابتوموماب إستافيناتوكس]]<ref name=WHOList96 /> || || Fab || فأر || [[5T4]] || non-small cell lung carcinoma, [[renal cell carcinoma]]
|-
| [[نارناتوماب]]<ref name=Narnatumab /> || || mab || بشري || RON || سرطان
|-
| [[ناتاليزوماب]] || Tysabri || mab || مأنسن || [[integrin]] α<sub>4</sub> || [[التصلب اللويحي]] و[[داء كرون]]
السطر 366 ⟵ 365:
| [[نيباكوماب]] || || mab || بشري || [[endotoxin]] || [[إنتان]]
|-
| [[نسيتوموماب]]<ref name=WHOList100 /> || || mab || بشري || [[Epidermal growth factor receptor|EGFR]] || non-small cell lung carcinoma
|-
| [[نريليموماب]] || || mab || فأر || [[TNF-α]] || ؟
|-
| [[نسفاكوماب]]<ref name=Nesvacumab /> || || mab || بشري || [[angiopoietin 2]] || سرطان
|-
| [[نيموتوزوماب]]<ref name=WHOList94 /><ref name=WHOList56 /> || Theracim, Theraloc || mab || مأنسن || [[epidermal growth factor receptor|EGFR]] || squamous cell carcinoma و[[سرطان الرأس والعنق]] و[[سرطان البلعوم الأنفي]] و[[ورم دبقي|الورم الدبقي]]
|-
| [[نيفولوماب]]<ref name=Nivolumab /> || || mab || بشري || IgG4 || سرطان
|-
| [[نوفيتوموماب مربنتان]] || Verluma || Fab || فأر || ؟ || سرطان (تشخيص)
السطر 380 ⟵ 379:
| [[أوكاراتوزوماب]]<ref name=Ocaratuzumab/> || || mab || مأنسن || [[CD20]] || سرطان
|-
| [[أوكرليزوماب]]<ref name=WHOList94 /> || || mab || مأنسن || [[CD20]] || [[التهاب المفاصل الروماتويدي]] و[[الذئبة الحمامية]]... الخ..
|-
| [[أودوليموماب]] || || mab || فأر || [[LFA-1]] ([[CD11a]]) || منع [[رفض الطعم]] والأمراض المناعية
|-
| [[أوفاتوموماب]]<ref name=WHOList93 /> || Arzerra || mab || بشري || [[CD20]] || [[ابيضاض الدم الليمفاوي المزمن]]... الخ.
|-
| [[أولاراتوماب]] || || mab || بشري || [[Platelet-derived growth factor receptor alpha|PDGF-R α]] || سرطان
|-
| [[أولوكيزوماب]]<ref name=WHOList103 /> || || mab || مأنسن || [[Interleukin 6|IL6]] || ؟
|-
| [[أوماليزوماب]]<ref name=WHOList84 /> || Xolair || mab || مأنسن || [[IgE]] [[Fc region]] || [[ربو|الربو التحسسي]]
|-
| [[أونارتوزوماب]]<ref name=Onartuzumab /> || || mab || مأنسن || human scatter factor receptor kinase || سرطان
|-
| [[أوبوتوزوماب موناتوكس]]<ref name=WHOList100 /> || || scFv || مأنسن || [[EpCAM]] || سرطان
|-
| [[أوريغوفوماب]]<ref name=WHOList86 /> || OvaRex || mab || فأر || [[CA-125]] || [[سرطان المبيض]]
|-
| [[أورتيكوماب]]<ref name=WHOList107 /> || || mab || بشري || [[oxidized low-density lipoprotein|oxLDL]] || ؟
|-
| [[أوتليكسيزوماب]]<ref name=WHOList98 /> || || mab || مجانس/مأنسن || [[CD3 (immunology)|CD3]] || [[سكري النمط الأول]]
|-
| [[أوكسلوماب]]<ref name=Oxelumab /> || || mab || بشري || [[OX-40]] || ال[[ربو]]
|-
| [[أوزانيزوماب]]<ref name=Ozanezumab /> || || mab || مأنسن || NOGO-A || ALS and [[التصلب اللويحي]]
|-
| [[أوزوراليزوماب]]<ref name=Ozoralizumab /> || || mab || مأنسن || ''[[لاما]]'' || inflammation
|-
| [[باغيباكسيماب]]<ref name=WHOList93 /> || || mab || مجانس|| [[lipoteichoic acid]] || [[إنتان]] (''[[عنقودية|عنقودي]]'')
|-
| [[باليفيزوماب]] || Synagis, Abbosynagis || mab || مأنسن || بروتين ف [[فيروس مخلوي تنفسي|للفيروس المخلوي التنفسي]] || [[فيروس مخلوي تنفسي|الفيروس المخلوي التنفسي]] (منع)
|-
| [[بانيتوموماب]]<ref name=WHOList91 /> || Vectibix || mab || بشري || [[epidermal growth factor receptor|EGFR]] || [[سرطان القولون]]
|-
| [[بانوباكوماب]]<ref name=WHOList100 /> || || mab || بشري || ''[[الزائفة الزنجارية]]'' || عدوى ''[[الزائفة الزنجارية]]''
|-
| [[بارساتوزوماب]]<ref name=WHOList107 /> || || mab || بشري || [[EGFL7]] || سرطان
|-
| [[باسكوليزوماب]]<ref name=WHOList87 /> || || mab || مأنسن || [[Interleukin 4|IL-4]] || ال[[ربو]]
|-
| [[باتكليزوماب]]<ref name=WHOList105 /> || || mab || مأنسن || [[lymphotoxin alpha|LTA]] || [[عامل نخر الورم]]
|-
| [[باتريتوماب]]<ref name=WHOList106 /> || || mab || بشري || [[HER3]] || سرطان
|-
| [[بمتوموماب]] || Theragyn || ؟ || فأر || [[MUC1]] || سرطان
|-
| [[بيراكيزوماب]]<ref name=WHOList107 /> || || mab || مأنسن || [[IL17A]] || ؟
|-
| [[برتوزوماب]] || Omnitarg || mab || مأنسن || [[HER2/neu]] || سرطان
|-
| [[بيكسليزوماب]]<ref name=WHOList85 /> || || scFv || مأنسن || [[Complement component 5|C5]] || للتقليل من الأعراض الجانبية ل[[جراحة القلب]]
|-
| [[بيديليزوماب]]<ref name=Pidilizumab /> || || mab || مأنسن || PD-1 || سرطان والأمراض المعدية
|-
| [[بينتوموماب]] || || mab || فأر || [[adenocarcinoma]] antigen || [[adenocarcinoma]] (imaging)
|-
| [[بلاكولوماب]]<ref name=Placulumab /> || || mab || بشري || human TNF || ؟
|-
| [[بونيزوماب]]<ref name=Ponezumab /> || || mab || مأنسن ||human [[beta-amyloid]] || [[مرض ألزهايمر]]
|-
| [[بريليكسيماب]] || || mab || مجانس || [[كتلة التمايز 4]] || [[داء كرون]] و[[التصلب اللويحي]]
السطر 446 ⟵ 445:
| [[برو 140]] || || ؟ || مأنسن || [[CCR5]] || [[متلازمة العوز المناعي المكتسب]]
|-
| [[كويليزوماب]]<ref name=WHOList106 /> || || mab || مأنسن || IGHE || ؟
|-
| [[راكوتوموماب]]<ref name=WHOList100 /> || || mab || فأر || ''N''-[[glycolylneuraminic acid]] || سرطان
|-
| [[رادريتوماب]]<ref name=WHOList104 /> || || mab || بشري || [[fibronectin]] extra domain-B || سرطان
|-
| [[رافيفيروماب]]<ref name=WHOList99 /> || || mab || بشري || البروتين السكري لفيروس [[داء الكلب]] || [[داء الكلب]] (وقاية)
|-
| [[راميسيروماب]] || || mab || بشري || [[VEGFR2]] || الأورام الصلبة
|-
| [[رانيبيزوماب]]<ref name=WHOList90 /> || Lucentis || Fab || مأنسن || [[VEGF-A]] || [[التنكس البقعي]] (النوع الرطب)
|-
| [[راكسيباكوماب]]<ref name=WHOList92 /> || || mab || بشري || توكسين والمستضد الواقي [[الجمرة الخبيثة|للجمرة الخبيثة]] || الجمرة الخبيثة (الوقاية والعلاج)
|-
| [[راغيفيروماب]] || || mab || بشري || البروتين السكري ب [[فيروس مضخم للخلايا|للفيروس المضخم للخلايا]] || عدوى [[فيروس مضخم للخلايا|الفيروس المضخم للخلايا]]
|-
| [[رسليزوماب]]<ref name=WHOList85 /> || || mab || مأنسن || [[Interleukin 5|IL-5]] || [[التهاب|التهابات]]ات المجاري التنفسية والجلد القناة الهضمية
|-
| [[ريلوتوموماب]]<ref name=Rilotumumab /> || || mab || بشري || [[hepatocyte growth factor|HGF]] || الأورام الصلبة
|-
| [[ريتوكسيماب]] || MabThera, Rituxan || mab || مجانس || [[CD20]] || [[ورم لمفي|الأورام اللمفية]] وحالات [[ابيضاض الدم]] وبعض [[أمراض المناعة الذاتية]]
السطر 470 ⟵ 469:
| [[روباتوموماب]] || || mab || بشري || [[IGF-1 receptor]] || سرطان
|-
| [[روليدوماب]]<ref name=WHOList103 /> || || mab || بشري || [[RHD (gene)|RHD]] || ؟
|-
| [[روموسوزوماب]]<ref name=Romosozumab /> || || mab || مأنسن || [[scleroscin]] || [[تخلخل العظم]]
|-
| [[رونتاليزوماب]]<ref name=Rontalizumab /> || || mab || مأنسن || [[Interferon-alpha|IFN-α]] || [[الذئبة الحمامية الجهازية]]
|-
| [[روفيليزوماب]] || LeukArrest || mab || مأنسن || [[CD11]], [[CD18]] || [[haemorrhagic shock]] etc.
|-
| [[روبليزوماب]]<ref name=WHOList83 /> || Antova || mab || مأنسن || [[CD154]] (CD40L) || [[التهاب المفاصل الروماتويدي]]
|-
| [[ساماليزوماب]]<ref name=Samalizumab /> || || mab || مأنسن || [[CD200]] || سرطان
|-
| [[ساريلوماب]]<ref name=Sarilumab /> || || mab || بشري || [[Interleukin 6|IL6]] || [[التهاب المفاصل الروماتويدي]] و[[التهاب الفقار المقسط]]
|-
| [[ساتوموماب بنديتيد]] || || mab || فأر || [[Tumor-associated glycoprotein 72|TAG-72]] || سرطان (تشخيص)
|-
| [[سيكوكينوماب]]<ref name=Secukinumab /> || || mab || بشري || [[IL-17A]] || [[uveitis]], [[التهاب المفاصل الروماتويدي]] وال[[صداف]]
|-
| [[سيفيروماب]] || || ؟ || بشري || [[cytomegalovirus]] || cytomegalovirus infection
السطر 492 ⟵ 491:
| [[سيبروتوزوماب]] || || mab || مأنسن || [[FAP (gene)|FAP]] || سرطان
|-
| [[سيفاليموماب]]<ref name=Sifalimumab /> || || mab || مأنسن || [[Interferon-alpha|IFN-α]] || [[الذئبة الحمامية الجهازية]], [[dermatomyositis]], [[polymyositis]]
|-
| [[سلتوكسيماب]] || || mab || مجانس || [[interleukin-6|IL-6]] || سرطان
|-
| [[سمتوزوماب]]<ref name=WHOList107 /> || || mab || مأنسن || [[LOXL2]] || ؟
|-
| [[سبليزوماب]]<ref name=WHOList87 /> || || mab || مأنسن || [[CD2]] || ال[[صداف]], [[داء الطعم حيال الثوي]] (منع)
|-
| [[سيروكوماب]]<ref name=Sirukumab /> || || mab || بشري || [[Interleukin 6|IL-6]] || [[التهاب المفاصل الروماتويدي]]
|-
| [[سولانيزوماب]]<ref name=WHOList100 /> || || mab || مأنسن || [[beta amyloid]] || [[مرض ألزهايمر]]
|-
| [[سوليتوماب]]<ref name=WHOList106 /> || || mab || فأر || [[EPCAM]] || ؟
|-
| [[سونبسيزوماب]]<ref>{{pmid|18781584}}</ref> || || ؟ || مأنسن || [[sphingosine-1-phosphate]] || [[Choroidal neovascularization|choroidal]] and [[retina]]l [[neovascularization]]
|-
| [[سونتوزوماب]]<ref name=WHOList56 /> || || mab || مأنسن || episialin || ؟
|-
| [[ستامولوماب]]<ref name=WHOList94 /><ref name=WHOList56/> || || mab || بشري || [[myostatin]] || muscular dystrophy
|-
| [[سوليسوماب]] || LeukoScan || Fab' || فأر || NCA-90 (granulocyte antigen) || [[التهاب العظم والنقي]] (imaging)
|-
| [[سوفيزوماب]]<ref name=WHOList102 /> || || mab || مأنسن || [[HIV-1]] || عدوى فايروسية
|-
| [[تابالوماب]]<ref name=Tabalumab /> || || mab || بشري || [[B-cell activating factor|BAFF]] || سرطانات الخلايا البائية
|-
| [[تاكاتوزوماب تتراكسيتان]] || AFP-Cide || mab || مأنسن || [[alpha-fetoprotein]] || سرطان
|-
| [[تادوسيزوماب]]<ref name=WHOList56 /> || || Fab || مأنسن || [[integrin]] α<sub>IIb</sub>β<sub>3</sub> || [[تداخل تاجي جلدي]]
|-
| [[تاليزوماب]] || || mab || مأنسن || [[IgE]] || [[allergic reaction]]
|-
| [[تانيزوماب]]<ref name=WHOList99 /> || || mab || مأنسن || [[عامل نمو الأعصاب|NGF]] || ال[[ألم]]
|-
| [[تابليتوموماب بابتوكس]]<ref name=WHOList84/> || || mab || فأر || [[CD19]] || سرطان{{حقيقة|date=November 2009}}
|-
| [[تيفيبازوماب]]<ref name=WHOList92 /> || Aurexis || mab || مأنسن || [[clumping factor A]] || عدوى ''[[عنقودية ذهبية|العنقودية الذهبية]]''
|-
| [[تيليموماب آريتوكس]] || || Fab || فأر || ؟ || ؟
|-
| [[تيناتوموماب]]<ref name=WHOList98 /> || || mab || فأر || [[tenascin C]] || سرطان
|-
| [[تنليكسيماب]]<ref name=WHOList87 /> || || mab || مجانس || [[CD40]] || ؟
|-
| [[تبليزوماب]]<ref name=WHOList97 /> || || mab || مأنسن || [[CD3 (immunology)|CD3]] || [[سكري النمط الأول]]
|-
| [[تبروتوموماب]]<ref name=Teprotumumab /> || || mab || بشري || [[CD221]] || أورام الدم
|-
| [[TGN1412]] || || ؟ || مأنسن || [[CD28]] || [[ابيضاض الدم الليمفاوي المزمن]] و[[التهاب المفاصل الروماتويدي]]
السطر 544 ⟵ 543:
| [[تيسيليموماب]] (= tremelimumab) || || mab || بشري || [[CTLA-4]] || سرطان
|-
| [[تلدراكيزوماب]]<ref name=Tildrakizumab /> || || mab || مأنسن || [[Interleukin 23|IL23]] || الأمراض الإلتهابية ذات الأصل المناعي
|-
| [[تيغاتوزوماب]]<ref name=WHOList98 /> || || mab || مأنسن || [[TRAIL-R2]] || سرطان
|-
| [[TNX-650]] || || ؟ || مأنسن || [[interleukin 13|IL-13]] || [[لمفومة هودجكين]]
|-
| [[توسيليزوماب]]<ref name=WHOList90 /> (= atlizumab) || Actemra, RoActemra || mab || مأنسن || [[IL-6 receptor]] || [[التهاب المفاصل الروماتويدي]]
|-
| [[توراليزوماب]]<ref name=WHOList87 /> || || mab || مأنسن || [[CD154]] (CD40L) || [[التهاب المفاصل الروماتويدي]], lupus nephritis etc.
|-
| [[توسيتوموماب]] || Bexxar || ؟ || فأر || [[CD20]] || [[follicular lymphoma]]
|-
| [[ترالوكينوماب]]<ref name=Tralokinumab /> || || mab || بشري || [[Interleukin 13|IL-13]] || ال[[ربو]]... الخ
|-
| [[ترازتوموماب]] || Herceptin || mab || مأنسن || [[HER2/neu]] || [[سرطان الثدي]]
السطر 562 ⟵ 561:
| [[TRBS07]]<ref>{{cite journal | last1=Ruf| first1=P | last2=et al | title= Two new trifunctional antibodies for the therapy of human malignant melanoma | journal=International Journal of Cancer | volume=108 | pages=725–732 | year=2004 | pmid=14696099 | doi=10.1002/ijc.11630 | first2=M | last3=Ellwart | first3=J | last4=Wosch | first4=S | last5=Kusterer | first5=E | last6=Lindhofer | first6=H | issue=5}}</ref> || Ektomab || 3funct || ؟ || GD2 || [[ورم ميلانيني]]
|-
| [[تريغاليزوماب]]<ref name=WHOList104 /> || || mab || مأنسن || [[كتلة التمايز 4]] || ؟
|-
| [[ترمليموماب]] || || mab || بشري || [[CTLA-4]] || سرطان
|-
| [[توكوتوزوماب سلموليوكين]]<ref name=WHOList94 /><ref name=WHOList56 /> || || mab || مأنسن || [[EpCAM]] || سرطان
|-
| [[توفيروماب]] || || ؟ || بشري || فيروس [[التهاب الكبد ب]] || [[التهاب الكبد ب]] المزمن
|-
| [[أوبليتوكسيماب]]<ref name=WHOList104 /> || || mab || مجانس || [[MS4A1]] || سرطان
|-
| [[أوريلوماب]]<ref name=Urelumab /> || || mab || بشري || [[4-1BB]] || سرطان... الخ
|-
| [[أورتوكسازوماب]]<ref name=WHOList90 /> || || mab || مأنسن || ''[[إشريكية قولونية|الإشريكية القولونية]]'' || الإسهال الذي سببه ''[[إشريكية قولونية|الإشريكية القولونية]]''
|-
| [[أوستكينوماب]]<ref name=WHOList99 /> || Stelara || mab || بشري || [[Interleukin 12|IL-12]], [[Interleukin 23|IL-23]] || [[التصلب اللويحي]] وال[[صداف]] و[[التهاب المفاصل الصدافي]]
|-
| [[فاباليكسيماب]]<ref name=WHOList87 /> || || mab || مجانس || [[AOC3]] (VAP-1) || ؟
|-
| [[فاتليزوماب]]<ref name=WHOList105 /> || || mab || مأنسن || [[ITGA2]] || ؟
|-
| [[فيدوليزوماب]] || || mab || مأنسن || [[integrin]] α<sub>4</sub>β<sub>7</sub> || [[داء كرون]] و[[التهاب القولون التقرحي]]
|-
| [[فلتوزوماب]]<ref name=WHOList98 /> || || mab || مأنسن || [[CD20]] || [[لمفومة لاهودجكينية]]
|-
| [[فيباليموماب]] || || mab || فأر || [[AOC3]] (VAP-1) || الإلتهاب
|-
| [[فيسنكوماب]]<ref name=WHOList104 /> || || mab || بشري || [[NRP1]] || ؟
|-
| [[فيسيليزوماب]]<ref name=WHOList84 /> || Nuvion || mab || مأنسن || [[CD3 (immunology)|CD3]] || [[داء كرون]] و[[التهاب القولون التقرحي]]
|-
| [[فولوسيكسيماب]]<ref name=WHOList93 /> || || mab || مجانس || [[integrin]] α<sub>5</sub>β<sub>1</sub> || الأورام الصلبة
|-
| [[فورسيتوزوماب مافودوتين]]<ref name="Vorsetuzumab mafodotin" /> || || mab || مأنسن || سرطان ||
|-
| [[فوتوموماب]] || HumaSPECT || mab || بشري || [[tumor antigen]] CTAA16.88 || [[سرطان القولون]]
السطر 600 ⟵ 599:
| [[زالوتوموماب]]<ref name=WHOList93/> || HuMax-EGFr || mab || بشري || [[Epidermal growth factor receptor|EGFR]] || [[سرطان الرأس والعنق|سرطان الخلايا الطلائية للرأس والعنق]]
|-
| [[زانوليموماب]]<ref name=WHOList90 /> || HuMax-CD4 || mab || بشري || [[كتلة التمايز 4]] || [[التهاب المفاصل الروماتويدي]], ال[[صداف]] و[[ورم لمفي|ورم الخلايا التائية اللمفي]]
|-
| [[زاتوكسيماب]]<ref name=WHOList107 /> || || mab || مجانس || [[HER1]] || سرطان
|-
| [[زيراليموماب]]<ref name=WHOList84 /> || || mab || بشري || [[باسيجين]] (basigin) || ؟
|-
| [[زوليموماب آريتوكس]] || || mab || فأر || [[CD5 (protein)|CD5]] || [[الذئبة الحمامية الجهازية]] و[[داء الطعم حيال الثوي]]
|-
| [[بيماغروماب]]<ref name=WHOList108 /> || || mab || human || [[ACVR2B]] || [[myostatin]] inhibitor
|-
| [[كونسيزوماب]]<ref name=WHOList108 /> || || mab || مأنسن || [[tissue factor pathway inhibitor|TFPI]] || [[نزف]]
|-
| [[لودلسيزوماب]]<ref name=WHOList108 /> || || mab || مأنسن || [[PCSK9]] || [[ارتفاع الكوليسترول]]
|-
| [[بيناتوزوماب فيدوتين]]<ref name=WHOList108 /> || || mab || مأنسن || [[CD22]] || سرطان
|-
| [[بولاتوزوماب فيدوتين]]<ref name=WHOList108 /> || || mab || مأنسن || [[CD79B]] || ?
|-
| [[بريتوكساكسيماب]]<ref name=WHOList108 /> || || mab || مجانس || ''[[إشريكية قولونية|E. coli]]'' [[shiga toxin]] type-1 || ?
|-
| [[سيريبانتوماب]]<ref name=WHOList108 /> || || mab || بشري || [[ERBB3]] || cancer
|-
| [[سيتوكساكسيماب]]<ref name=WHOList108 /> || || mab || مجانس || ''[[إشريكية قولونية|E. coli]]'' [[shiga toxin]] type-1 || ?
|-
| [[إلديلوماب]]<ref name=Eldelumab /> || || mab || بشري || [[إنترفيرون]] gamma-induced protein || [[داء كرون]] و[[التهاب القولون التقرحي]]
|}
 
== المصادر ==
{{مراجع|2|refs=<ref name=WHOList95>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95 | journal = WHO Drug Information | volume = 20 | issue = 2 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf | format=PDF}}</ref><ref name=WHOList90>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | format=PDF}}</ref><ref name=WHOList99>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99 | journal = WHO Drug Information | volume = 22 | issue = 2 | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf | format=PDF}}</ref><ref name=WHOList98>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 | journal = WHO Drug Information | volume = 21 | issue = 4 | year = 2007 | url = http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf | format=PDF}}</ref><ref name=WHOList83>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83 | journal = WHO Drug Information | volume = 14 | issue = 2 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf | format=PDF}}</ref><ref name=WHOList87>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87 | journal = WHO Drug Information | volume = 16 | issue = 2 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf | format=PDF}}</ref><ref name=WHOList88>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88 | journal = WHO Drug Information | volume = 17 | issue = 1 | year = 2003 | url = http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf | format=PDF}}</ref><ref name=WHOList104>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref><ref name=WHOList93>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93 | journal = WHO Drug Information | volume = 19 | issue = 2 | year = 2008 | url = http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf | format=PDF}}</ref><ref name=WHOList92>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92 | journal = WHO Drug Information | volume = 18 | issue = 4 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf | format=PDF}}</ref><ref name=WHOList105>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}</ref><ref name="Brentuximab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf}}</ref><ref name=WHOList66>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66 | journal = WHO Drug Information | volume = 5 | issue = 4 | year = 1991 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf | format=PDF}}</ref><ref name=Briakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf}}</ref><ref name=WHOList85>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85 | journal = WHO Drug Information | volume = 15 | issue = 2 | year = 2001 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | format=PDF}}</ref><ref name=WHOList97>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97 | journal = WHO Drug Information | volume = 21 | issue = 2 | year = 2007 | url = http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf | format=PDF}}</ref><ref name=WHOList51>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | format=PDF}}</ref><ref name=WHOList106>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf | format=PDF}}</ref><ref name=WHOList56>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56 | journal = WHO Drug Information | volume = 20 | issue = 3 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf | format=PDF}}</ref><ref name="Clivatuzumab tetraxetan">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf}}</ref><ref name=WHOList77>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf | format=PDF}}</ref><ref name=Crenezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf}}</ref><ref name=WHOList84>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84 | journal = WHO Drug Information | volume = 14 | issue = 4 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | format=PDF}}</ref><ref name=Amatuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf}}</ref><ref name=WHOList86>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86 | journal = WHO Drug Information | volume = 16 | issue = 12 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf | format=PDF}}</ref><ref name=Brodalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf}}</ref><ref name=WHOList101>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101 | journal = WHO Drug Information | volume = 23 | issue = 2 | year = 2009 | url = http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf | format=PDF}}</ref><ref name=Carlumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/carlumab.pdf}}</ref><ref name=WHOList91>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91 | journal = WHO Drug Information | volume = 18 | issue = 2 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf | format=PDF}}</ref><ref name=WHOList94>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94 | journal = WHO Drug Information | volume = 19 | issue = 4 | year = 2005 | url = http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf | format=PDF}}</ref><ref name=WHOList107>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}</ref><ref name=Enavatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref><ref name=Enokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf}}</ref><ref name=Ensituximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf}}</ref><ref name=WHOList96>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96 | journal = WHO Drug Information | volume = 20 | issue = 4 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf | format=PDF}}</ref><ref name=Etrolizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf}}</ref><ref name=Fezakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf}}</ref><ref name=Ficlatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref><ref name=WHOList100>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy) | journal = WHO Drug Information | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf | format=PDF}}</ref><ref name=WHOList103>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}</ref><ref name=WHOList102>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102 | journal = WHO Drug Information | volume = 23 | issue = 4 | year = 2009 | url = http://www.who.int/medicines/services/inn/FINAL_PL102.pdf | format=PDF}}</ref><ref name=Fresolimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf}}</ref><ref name=Fulranumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf}}</ref><ref name=Gevokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf}}</ref><ref name=Icrucumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf}}</ref><ref name=Dalotuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf}}</ref><ref name=Intetumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}</ref><ref name=Drozitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf}}</ref><ref name=Lebrikizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf}}</ref><ref name=Ixekizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf}}</ref><ref name=Rilotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf}}</ref><ref name=Flanvotumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf}}</ref><ref name=Rontalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf}}</ref><ref name=Ganitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf}}</ref><ref name=Sifalimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf}}</ref><ref name=Clazakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Clazakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/clazakizumab.pdf}}</ref><ref name=Mavrilimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf}}</ref><ref name=Mogamulizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf}}</ref><ref name="Moxetumomab pasudotox">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf}}</ref><ref name=Alirocumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Alirocumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/alirocumab.pdf}}</ref><ref name=Narnatumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf}}</ref><ref name=Demcizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Demcizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/demcizumab.pdf}}</ref><ref name=Nivolumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nivolumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nivolumab.pdf}}</ref><ref name=Actoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Actoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf}}</ref><ref name=Onartuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf}}</ref><ref name=Bezlotoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Bezlotoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/bezlotoxumab.pdf}}</ref><ref name=Oxelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf}}</ref><ref name=Dupilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dupilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf}}</ref><ref name=Ozoralizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf}}</ref><ref name=Dusigitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dusigitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf}}</ref><ref name=Ponezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf}}</ref><ref name=WHOList108>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf | format=PDF}}</ref><ref name=Samalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}}</ref><ref name=Fasinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fasinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fasinumab.pdf}}</ref><ref name=Secukinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf}}</ref><ref name="ALD518">{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire|title=BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody|date=10 November 2009|publisher=Genetic Engineering & Biotechnology News}}</ref><ref name=Sirukumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf}}</ref><ref name="IMA-638">{{cite web |url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing | year = 2008 |publisher = [[Wyeth]]|accessdate=November 19, 2008 |archiveurl = http://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate = June 12, 2008}}</ref><ref name=Tabalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf}}</ref><ref name=Ch1418>{{cite web|url=http://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business|title=United Therapeutics 10-K report|accessdate=5 November 2011}}</ref><ref name=Urelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref><ref name=NCT00883896>{{ClinicalTrialsGov|NCT00883896|Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis}}</ref><ref name=Teprotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf}}</ref><ref name=NCT00563524>{{ClinicalTrialsGov|NCT00563524|Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis}}</ref><ref name=Tralokinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf}}</ref><ref name="Glembatumumab">[[National Cancer Institute|NCI]] Drug Dictionary: [http://www.cancer.gov/drugdictionary/?CdrID=599456 Glemtumumab vedotin]</ref><ref name=Romosozumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf}}</ref><ref name=GS6624>{{cite web|url=http://edgar.sec.gov/Archives/edgar/data/882095/000119312511050041/d10k.htm|title=Gilead Sciences 10-K report|accessdate=5 November 2011}}</ref><ref name=Sarilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf}}</ref><ref name=NCT00537381>{{ClinicalTrialsGov|NCT00537381|A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer}}</ref><ref name=Ocaratuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ocaratuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ocaratuzumab.pdf}}</ref><ref name=NCT00246012>{{ClinicalTrialsGov|NCT00246012|A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma}}</ref><ref name=Placulumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Placulumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/placulumab.pdf}}</ref><ref name=Nesvacumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nesvacumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf}}</ref><ref name=Ozanezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozanezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf}}</ref><ref name=Pidilizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Pidilizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf}}</ref><ref name="Vorsetuzumab mafodotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/vorsetuzumab_mafodotin.pdf}}</ref><ref name=Tildrakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tildrakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf}}</ref><ref name=Eldelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Eldelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf}}</ref>
{{مراجع|2|refs=
<ref name=WHOList95>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95 | journal = WHO Drug Information | volume = 20 | issue = 2 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf | format=PDF}}</ref>
<ref name=WHOList90>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | format=PDF}}</ref>
<ref name=WHOList99>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99 | journal = WHO Drug Information | volume = 22 | issue = 2 | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf | format=PDF}}</ref>
<ref name=WHOList98>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 | journal = WHO Drug Information | volume = 21 | issue = 4 | year = 2007 | url = http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf | format=PDF}}</ref>
<ref name=WHOList83>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83 | journal = WHO Drug Information | volume = 14 | issue = 2 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf | format=PDF}}</ref>
<ref name=WHOList87>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87 | journal = WHO Drug Information | volume = 16 | issue = 2 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf | format=PDF}}</ref>
<ref name=WHOList88>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88 | journal = WHO Drug Information | volume = 17 | issue = 1 | year = 2003 | url = http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf | format=PDF}}</ref>
<ref name=WHOList104>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref>
<ref name=WHOList93>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93 | journal = WHO Drug Information | volume = 19 | issue = 2 | year = 2008 | url = http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf | format=PDF}}</ref>
<ref name=WHOList92>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92 | journal = WHO Drug Information | volume = 18 | issue = 4 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf | format=PDF}}</ref>
<ref name=WHOList105>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}</ref>
<ref name="Brentuximab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf}}</ref>
<ref name=WHOList66>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66 | journal = WHO Drug Information | volume = 5 | issue = 4 | year = 1991 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf | format=PDF}}</ref>
<ref name=Briakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf}}</ref>
<ref name=WHOList85>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85 | journal = WHO Drug Information | volume = 15 | issue = 2 | year = 2001 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | format=PDF}}</ref>
<ref name=WHOList97>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97 | journal = WHO Drug Information | volume = 21 | issue = 2 | year = 2007 | url = http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf | format=PDF}}</ref>
<ref name=WHOList51>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | format=PDF}}</ref>
<ref name=WHOList106>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf | format=PDF}}</ref>
<ref name=WHOList56>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56 | journal = WHO Drug Information | volume = 20 | issue = 3 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf | format=PDF}}</ref>
<ref name="Clivatuzumab tetraxetan">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf}}</ref>
<ref name=WHOList77>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf | format=PDF}}</ref>
<ref name=Crenezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf}}</ref>
<ref name=WHOList84>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84 | journal = WHO Drug Information | volume = 14 | issue = 4 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | format=PDF}}</ref>
<ref name=Amatuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf}}</ref>
<ref name=WHOList86>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86 | journal = WHO Drug Information | volume = 16 | issue = 12 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf | format=PDF}}</ref>
<ref name=Brodalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf}}</ref>
<ref name=WHOList101>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101 | journal = WHO Drug Information | volume = 23 | issue = 2 | year = 2009 | url = http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf | format=PDF}}</ref>
<ref name=Carlumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/carlumab.pdf}}</ref>
 
<ref name=WHOList91>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91 | journal = WHO Drug Information | volume = 18 | issue = 2 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf | format=PDF}}</ref>
<ref name=WHOList94>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94 | journal = WHO Drug Information | volume = 19 | issue = 4 | year = 2005 | url = http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf | format=PDF}}</ref>
<ref name=WHOList107>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}</ref>
<ref name=Enavatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref>
<ref name=Enokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf}}</ref>
<ref name=Ensituximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf}}</ref>
<ref name=WHOList96>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96 | journal = WHO Drug Information | volume = 20 | issue = 4 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf | format=PDF}}</ref>
<ref name=Etrolizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf}}</ref>
<ref name=Fezakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf}}</ref>
<ref name=Ficlatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref>
<ref name=WHOList100>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy) | journal = WHO Drug Information | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf | format=PDF}}</ref>
<ref name=WHOList103>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}</ref>
<ref name=WHOList102>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102 | journal = WHO Drug Information | volume = 23 | issue = 4 | year = 2009 | url = http://www.who.int/medicines/services/inn/FINAL_PL102.pdf | format=PDF}}</ref>
<ref name=Fresolimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf}}</ref>
<ref name=Fulranumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf}}</ref>
<ref name=Gevokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf}}</ref>
<ref name=Icrucumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf}}</ref>
<ref name=Dalotuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf}}</ref>
<ref name=Intetumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}</ref>
<ref name=Drozitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf}}</ref>
<ref name=Lebrikizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf}}</ref>
<ref name=Ixekizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf}}</ref>
<ref name=Rilotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf}}</ref>
<ref name=Flanvotumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf}}</ref>
<ref name=Rontalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf}}</ref>
<ref name=Ganitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf}}</ref>
<ref name=Sifalimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf}}</ref>
<ref name=Clazakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Clazakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/clazakizumab.pdf}}</ref>
<ref name=Mavrilimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf}}</ref>
<ref name=Mogamulizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf}}</ref>
<ref name="Moxetumomab pasudotox">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf}}</ref>
<ref name=Alirocumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Alirocumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/alirocumab.pdf}}</ref>
<ref name=Narnatumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf}}</ref>
<ref name=Demcizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Demcizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/demcizumab.pdf}}</ref>
<ref name=Nivolumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nivolumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nivolumab.pdf}}</ref>
<ref name=Actoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Actoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf}}</ref>
<ref name=Onartuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf}}</ref>
<ref name=Bezlotoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Bezlotoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/bezlotoxumab.pdf}}</ref>
<ref name=Oxelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf}}</ref>
<ref name=Dupilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dupilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf}}</ref>
<ref name=Ozoralizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf}}</ref>
<ref name=Dusigitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dusigitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf}}</ref>
<ref name=Ponezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf}}</ref>
<ref name=WHOList108>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf | format=PDF}}</ref>
<ref name=Samalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}}</ref>
<ref name=Fasinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fasinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fasinumab.pdf}}</ref>
<ref name=Secukinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf}}</ref>
<ref name="ALD518">{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire|title=BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody|date=10 November 2009|publisher=Genetic Engineering & Biotechnology News}}</ref>
<ref name=Sirukumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf}}</ref>
<ref name="IMA-638">{{cite web |url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing | year = 2008 |publisher = [[Wyeth]]|accessdate=November 19, 2008 |archiveurl = http://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate = June 12, 2008}}</ref>
<ref name=Tabalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf}}</ref>
<ref name=Ch1418>{{cite web|url=http://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business|title=United Therapeutics 10-K report|accessdate=5 November 2011}}</ref>
<ref name=Urelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref>
<ref name=NCT00883896>{{ClinicalTrialsGov|NCT00883896|Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis}}</ref>
<ref name=Teprotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf}}</ref>
<ref name=NCT00563524>{{ClinicalTrialsGov|NCT00563524|Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis}}</ref>
<ref name=Tralokinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf}}</ref>
<ref name="Glembatumumab">[[National Cancer Institute|NCI]] Drug Dictionary: [http://www.cancer.gov/drugdictionary/?CdrID=599456 Glemtumumab vedotin]</ref>
<ref name=Romosozumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf}}</ref>
<ref name=GS6624>{{cite web|url=http://edgar.sec.gov/Archives/edgar/data/882095/000119312511050041/d10k.htm|title=Gilead Sciences 10-K report|accessdate=5 November 2011}}</ref>
 
<ref name=Sarilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf}}</ref>
<ref name=NCT00537381>{{ClinicalTrialsGov|NCT00537381|A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer}}</ref>
<ref name=Ocaratuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ocaratuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ocaratuzumab.pdf}}</ref>
<ref name=NCT00246012>{{ClinicalTrialsGov|NCT00246012|A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma}}</ref>
<ref name=Placulumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Placulumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/placulumab.pdf}}</ref>
 
<ref name=Nesvacumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nesvacumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf}}</ref>
<ref name=Ozanezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozanezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf}}</ref>
<ref name=Pidilizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Pidilizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf}}</ref>
<ref name="Vorsetuzumab mafodotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/vorsetuzumab_mafodotin.pdf}}</ref>
<ref name=Tildrakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tildrakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf}}</ref>
<ref name=Eldelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Eldelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf}}</ref>
 
}}
السطر 738 ⟵ 635:
[[تصنيف:أجسام مضادة وحيدة النسيلة]]
[[تصنيف:قوائم طبية]]
[[تصنيف:قوائم متعلقة بالأدوية]]
 
[[en:Liste d'anticorps monoclonaux]]
مجلوبة من «https://ar.wikipedia.org/wiki/قائمة_الأجسام_المضادة_وحيدة_النسيلة»